Science, technology, and innovation in pandemic times: Covid-19 implications

Autores

Palavras-chave:

Covid-19, Health Economic-Industrial Complex (HEIC), Science, Technology and Innovation in Health, Bibliometric Analysis, Collaboration Networks

Resumo

The paper analyzes the impacts of the COVID-19 pandemic on the organization of and incentive to science, technology, and innovation in health activities worldwide and nationally, focusing on two aspects. One of them is related to the adopted mechanisms of coordination of and support to these activities in order to manage the pandemic. The other is related to the recent evolution of scientific production on Covid-19. This study highlights the strategic importance of public research and incentive institutions in organizing and coordinating science, technology, and innovation in health activities and the growing incorporation of new technological platforms associated with Industry 4.0. However, there are worldwide asymmetries in the production of scientific knowledge. So, a strategic State approach is crucial in order to coordinate public and private interests regarding health production and guarantee the population’s access to health.

Downloads

Não há dados estatísticos.

Biografia do Autor

Marco Antonio Vargas, Centro Celso Furtado

Associate Professor at Fluminense Federal University, Department of Economic Sciences. PhD in Economics of Industry and Technology from the Rio de Janeiro Federal University; MSc and BSc in Economics from the Rio Grande do Sul Federal University. Coordinator of the Research Center for Industry, Energy, Territory and Innovation (NIETI/UFF).

Nathalia Guimarães Alves, Rio de Janeiro Federal University

PhD candidate in Industrial Economics of Technology at the Rio de Janeiro Federal University. MSc in Economics from Fluminense Federal University; BSc in Economics from the Rio de Janeiro Federal University.

Matias Mrejen, Institute for Health Policy Studies

Post-doctoral Researcher Fellow at the Institute of Health Policy Studies. PhD and MSc in Economics from Fluminense Federal University; BSc in Political Science from the National University of Rosario.

Referências

ABI YOUNES, G. et al. Covid-19: Insights from Innovation Economists. (Preprint). École Polytechnique Fédérale de Lausanne (EPFL), April 14th, 2020, p. 1-34. DOI: http://dx.doi.org/10.2139/ssrn.3575824.

BAKER, B. U. S. China and EU First Nationalism and Covid-19 Technology Hoarding Push the Rest of the World to the End of the Line. Health GAP. Global Access Project, June 5th, 2020. Availabre: https://healthgap.org/u-s-china-and-eu-first-nationalism-and-Covid-19-technology-hoarding-push-the-rest-of-the-world-to-the-end-of-the-line/. Access: Aug. 3rd, 2020.

CASAS, C. N. P. R. O complexo industrial da saúde na área farmacêutica: uma discussão sobre inovação e acesso no Brasil. 2009. Tese (Doutorado em Ciências na Área de Saúde Pública) – Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz, Rio de Janeiro, 2009.

COHEN, J. Unveiling ‘Warp Speed’, the White House’s America-first push for a coronavirus vaccine. Science, May 12th, 2020a. DOI: http://dx.doi.org/10.1126/science.abc7056.

COHEN, J. Operation Warp Speed’s opaque choices of Covid-19 vaccines draw Senate scrutiny. Science, July 2nd, 2020b. DOI: http://dx.doi.org/10.1126/science.abd6430.

DE NEGRI, F.; KOELLER, P. Public Policies for Research and Innovation in the Face of the Covid-19 Crisis. IPEA - Center for Research on Science, Technology and Society, April 6th, 2020. Available: https://www.ipea.gov.br/cts/en/all-contents/articles/articles/203-public-policies-for-research-and-innovation-in-the-face-of-the-covid-19-crisis-3. Access: July 30th, 2020.

FAPESP. Vacina em teste no Butantan terá R$ 82,5 milhões da Fapesp e do Todos pela Saúde. Agência FAPESP, 21 ago. 2020. Disponível em: https://agencia.fapesp.br/vacina-em-teste-no-butantan-tera-r-825-milhoes-da-fapesp-e-do-todos-pela-saude/33936/. Acesso em: 30 ago. 2020.

FIOCRUZ. Covid-19: Fiocruz firmará acordo para produzir vacina da Universidade de Oxford. Agência Fiocruz, jun. 2020. Disponível em: https://agencia.fiocruz.br/covid-19-fiocruz-firmara-acordo-para-produzir-vacina-da-universidade-de-oxford. Acesso em: 30 ago. 2020.

FRENTE PELA VIDA. Plano Nacional de Enfrentamento à Pandemia da Covid-19. Publicado em: 30 jun. 2020. Disponível em: http://cebes.org.br/site/wp-content/uploads/2020/07/PEP-COVID-19-minuta-15_vf.pdf. Acesso em: 30 ago. 2020.

GADELHA C. A. G. O complexo industrial da saúde e a necessidade de um enfoque dinâmico na economia da saúde. Ciência & Saúde Coletiva, v. 2, n. 8, p. 521-535. 2003.

HHS. Department of Health and Human Services. Trump Administration Announces Framework and Leadership For Operation Warp Speed. Publicado em: 15 maio 2020. Disponível em: https://www.hhs.gov/about/news/2020/05/15/trump-administration-announces-framework-and-leadership-for-operation-warp-speed.html. Acesso em 30 jul. 2020.

HHS. Fact Sheet Explaining Operation Warp Speed. Department of Health and Human Services, June 16th, 2020. Available: https://www.hhs.gov/about/news/2020/06/16/fact-sheet-explaining-operation-warp-speed.html. Access: Sept. 10th, 2020.

KUPFERSCHMIDT, K. ‘Vaccine Nationalism’ Threatens Global Plan to Distribute Covid-19 Shots Fairly. Science, July 28th, 2020. DOI: https://doi.org/10.1126/science.abe0601.

LIU, C. et al. Research and Development on Therapeutic Agents and Vaccines for Covid-19 and Related Human Coronavirus Diseases. ACS Central Science, v. 6, n. 3, p. 315-331, 2020. DOI: https://dx.doi.org/10.1021/acscentsci.0c00272.

OECD. Organisation for Economic Co-operation and Development. Treatments and a vaccine for COVID-19: the need for coordinating policies on R&D, manufacturing and access. In: Tackling coronavirus (COVID-19): contributing to a global effort. [S. l.]: OECD, May 29th, 2020. Available: https://read.oecd-ilibrary.org/view/?ref=133_133372-v717pcul4c&title=Treatments-and-a-vaccine-for-COVID-19-the-need-for-coordinating-policies-on-RD-manufacturing-and-access. Access: July 13th, 2020.

TELLEZ, V. M. The Covid-19 Pandemic: R&D and Intellectual Property Management for Access to Diagnostics, Medicines and Vaccines. Policy Brief, n. 73, p. 1-8, abr. 2020. Available: https://ssrn. com/abstract=3640229. Access: July 13th, 2020.

THE LANCET. Covid-19 in Brazil: “So what?”. The Lancet, v. 395, n. 10235, p. 1461, May 9th, 2020.

UNCTAD. United Nations Conference on Trade and Development. The need to protect science, tech- nology and innovation funding during and after the Covid-19 crisis. UNCTAD Policy Brief, n. 80, 2020. Available: https://unctad.org/en/PublicationsLibrary/presspb2020d4_en.pdf. Access: July 1st, 2020.

UNIFESP. Universidade Federal de São Paulo. Unifesp participará de teste de vacina para covid-19 desenvolvida por Oxford. UNIFESP, Campus São Paulo, 3 jun. 2020. Disponível em: https://www.unifesp.br/campus/sao/hidden/coronavirus/1383-unifesp-participara-de-teste-de-vaci-na-para-Covid-19-desenvolvida-por-oxford. Acesso em: 12 ago. 2020.

WTO. World Trade Organization. Trade in medical goods in the context of tackling COVID-19: Information note. [S. l.]: WTO, April 3rd, 2020. Available: https://www.wto.org/english/news_e/news20_e/ rese_03apr20_e.pdf. Access: July 30th, 2020.

Downloads

Publicado

2023-09-25

Como Citar

Vargas, M. A., Alves, N. G., & Mrejen, M. (2023). Science, technology, and innovation in pandemic times: Covid-19 implications. Cadernos Do Desenvolvimento, 16(28), 147–180. Recuperado de https://cadernosdodesenvolvimento.org.br/cdes/article/view/711

Edição

v. 16 n. 28 (2021): Dossier "Development, health and structural change: The Health Economic-Industrial Complex 4.0 in the context of Covid-19"

Seção

Dossier "Development, health and structural change: The HEIC 4.0 in the context of Covid-19"

Licença

Autores que publicam nesta revista concordam com os seguintes termos:

    1. Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista;
       
    2. Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista;
       
    3. Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado (Veja O Efeito do Acesso Livre).